deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
abiraterone plus ADT vs. androgen deprivation therapy (ADT) 2 0.63 [0.54; 0.72], 2 RCTs, I2=0% conclusive
unassessable degree of certainty